Quarterly Activity Report and Appendix C
Imagion Biosystems has released their Quarterly Activity Report for the period ended 30 September 2020 and Appendix C. Q3 Highlights Raised $4.7M (after…
Appendix 3Y — Change of Director's Interest Notice
Imagion Biosystems gave ASX information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Read…
Appendix 2A — Fully Paid Ordinary Shares
Imagion Biosystems has submitted "Appendix 2A — Application for quotation of +securities." Read Appendix 2A.
Vesting of Performance Rights
Imagion Biosystems has advised that 2,500,000 performance rights have vested and were issued as ordinary shares to Executive Chairman and CEO Bob Proulx today,…
Notice Pursuant to Section 708(5)(e) of the Corporations Act 2001
Imagion Biosystems gives notice that, on 20 October 2020 the Company issued 2,401,900 fully paid ordinary shares (Shares) in the Company as the result of…
IBX Secures Additional Capital — Shareholders Exercise Options
Imagion Biosystems announced that it has received a total of $143,157 for the exercise of options. Composed of $142,200 for 2,370,000 options exercisable at 6…
Imagion Biosystems Appoints Geoff Hollis as CFO
Imagion Biosystems has appointed Geoff Hollis as Chief Financial Officer. The appointment strengthens the Company’s management and leadership team as the…
HREC Approval for Phase I Study
Imagion Biosystems is pleased to report that it has received approval from the Human Research Ethics Committee (HREC) for the MagSense® HER2 Phase I study…
Issue of Unlisted Performance Options under EIP
Imagion Biosystems today announced "Issue of unlisted performance options under Equity Incentive Plan". Read the announcement.
Appendix 3G
The attached "Appendix 3G: Notification of issue, conversion or payment up of equity +securities" was released to market. View Appendix 3G.